|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunization with melanoma antigens conjugated to antibodies (Abs) specific for mouse CD169 efficiently induced gp100 and Trp2-specific T cell responses in mice.
|
30764534 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the TRP2-mRNA/α-GalCer-based multi-LP vaccine induced a significant therapeutic effect against a highly malignant B16-F10 melanoma tumor.
|
31460428 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that mannosylated Trp-2 and MPLA-loaded PBAE nano-vaccines can target and mature DCs, consequently boosting antigen-specific cytotoxic T lymphocyte activity against melanoma.
|
31593795 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice.
|
29355622 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using melanoma as the model cancer and Tyrosinase-related protein 2 (Trp2) peptide as the model antigen, we demonstrated that dispersion-stable LDH-based vaccine induced stronger cytotoxic T-lymphocyte (CTL) responses and significantly inhibited tumor growth in comparison with aggregated LDH-based vaccine.
|
29778982 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used two mouse models of melanoma termed B16.OVA and B16-F10 for testing the efficacy of OVA SIINFEKL-peptide-coated viruses and gp100-Trp2-peptide-coated viruses, respectively, and show that by coating the viral envelope with therapeutic peptides, the anti-tumor immunity and the number of tumor-specific CD8<sup>+</sup> T cells in the tumor microenvironment can be significantly enhanced.
|
30005865 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the combination treatment of RGP and tyrosinase-related protein 2 (TRP2) peptide, a melanoma self-antigen, protected mice from melanoma challenge.
|
30282011 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LCP mRNA vaccine encoding TRP2 elicited a robust antigen-specific cytotoxic T cell response and a humoral immune response in a C57BL/6 mouse model of B16F10 melanoma.
|
29249397 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice.
|
28273716 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SLA individually or mixed with uncharged glyolipid (lactosylarchaeol, LA) constituted efficacious carrier vesicles for entrapped antigens (ovalbumin or melanoma associated tyrosinase-related protein 2 [TRP-2]) and induction of strong cell-mediated responses in mice and protection against subsequent B16 melanoma tumor challenge.
|
28537465 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously developed a potent mannose-modified lipid calcium phosphate (LCP) nanoparticle (NP)-based Trp2 vaccine for melanoma therapy, but because this vaccine can induce a potent anti-tumor immune response only during the early stages of melanoma, poor tumor growth inhibition has been observed in more advanced melanoma models, likely due to the development of an immune-suppressive tumor microenvironment (TME).
|
27863995 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, therapeutic vaccination with pTRP2 and shIκBα delayed the growth of B16F10 melanoma subcutaneous tumors.
|
28666759 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
|
29296525 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A structural and functional relationship between DCT and CAV1 is first presented here in two human amelanotic melanoma cell lines, derived from vertical growth phase (MelJuSo) and metastatic (SKMel28) melanomas.
|
27053106 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion our data suggest that p53 repression critically controlled by TRP2 is not a general event in melanoma.
|
24475287 |
2014 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DCT depletion reduced p53 and pp53-Ser15 levels in WM266-4 melanoma and MC1R WT MB cells, while MC1R RHC MB cells displayed variable levels.
|
25346513 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DCT assessment shows specific antigen patterns with potential significance in the outcome of melanocytic lesions, connecting DCT, a mediator of a melanoma stress-resistant pathway, and an antiapoptotic molecule to DCT- phenotypes that are possibly more stable and stress resistant.
|
24709887 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human SmartDC-TRP2 generated with monocytes obtained from melanoma patients secreted endogenous cytokines associated with DC activation and stimulated TRP2-specific autologous T-cell expansion in vitro.
|
22428979 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To scan the human melanoma differentiation antigens TRP-1 and TRP-2 for HLA-DRB1*0301-restricted CD4+ T cell epitopes we applied the following methodology: Splenocytes of HLA-DRB1*0301-transgenic mice immunized with recombinant adenovirus encoding TRP-1 (Ad5.TRP-1) or TRP-2 (Ad5.TRP-2) were tested for their T cell reactivity against combinatorial TRP-1- and TRP-2-specific peptide libraries.
|
21152437 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study identifies a VRP-based vaccine able to elicit humoral immunity against TRP-2, which plays a role in melanoma immunotherapy and synergizes with tumor-specific CD8+ T cell responses.
|
20844763 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have investigated the therapeutic potential of a prototypic melanoma vaccine based on recombinant adenovirus expressing human dopachrome tautomerase in the B16F10 murine melanoma model.
|
18989352 |
2009 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the addition of ABT-737 to either a vaccine strategy involving priming with TRP-2 melanoma antigen peptide-pulsed DC and boosting with recombinant Listeria monocytogenes expressing the same melanoma antigen, or the adoptive transfer of TCR transgenic cells, did not result in superior antitumor activity against B16 murine melanoma.
|
18807035 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TRP-2 epitope was detected by IHC in 20/24 primary melanomas (83%), 9/9 metastatic melanomas (100%) and 4/6 nevi (67%).
|
18204435 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Here we studied a possible role of TRP-2 in the oxidative stress response in the amelanotic WM35 melanoma cell line.
|
18206123 |
2008 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
C57Bl/6J mice were injected subcutaneously with bone marrow derived dendritic cells (DCs) pulsed with a melanoma epitope (TRP2-P2/Agonist), melanoma epitope tyrosinase (TYR/Agonist), a nonfunctional reverse conformation C5a agonist bound to TYR(reverse peptide) or DMSO-PBS vehicle.
|
17986862 |
2007 |